RT Journal Article
T1 Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort.
A1 Obón-Santacana, Mireia
A1 Freisling, Heinz
A1 Peeters, Petra H
A1 Lujan-Barroso, Leila
A1 Ferrari, Pietro
A1 Boutron-Ruault, Marie-Christine
A1 Mesrine, Sylvie
A1 Baglietto, Laura
A1 Turzanski-Fortner, Renee
A1 Katzke, Verena A
A1 Boeing, Heiner
A1 Quirós, J Ramón
A1 Molina-Portillo, Elena
A1 Larrañaga, Nerea
A1 Chirlaque, María-Dolores
A1 Barricarte, Aurelio
A1 Khaw, Kay-Tee
A1 Wareham, Nick
A1 Travis, Ruth C
A1 Merritt, Melissa A
A1 Gunter, Marc J
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Naska, Androniki
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Tumino, Rosario
A1 Fiano, Valentina
A1 Galassom, Rocco
A1 Bueno-de-Mesquita, H B As
A1 Onland-Moret, N Charlotte
A1 Idahl, Annika
A1 Lundin, Eva
A1 Weiderpass, Elisabete
A1 Vesper, Hubert
A1 Riboli, Elio
A1 Duell, Eric J
K1 EPIC
K1 acrylamide
K1 endometrial cancer
K1 glycidamide
K1 hemoglobin adduct
AB Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1 : 0.84, 95%CI: 0.49-1.48; HRHbGA;Q5vsQ1 : 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI 
YR 2015
FD 2015-10-01
LK http://hdl.handle.net/10668/10249
UL http://hdl.handle.net/10668/10249
LA en
DS RISalud
RD Apr 19, 2025